Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • U.S. Department of War
  • Biomedical Advanced Research and Development Authority (HHSO100201700018C)
  • National Institutes of Health (COV3009)

This publication has 22 references indexed in Scilit: